Close Menu

BARCELONA – It will likely take more than information on a tumor's tissue of origin to effectively treat carcinomas of unknown primary site (CUP), according to negative Phase III clinical trial data presented this weekend at the European Society for Medical Oncology Congress.

That realization — together with results from retrospective analyses on tumors compiled by Foundation Medicine — has at least one international team pressing forward with a Phase II trial of genomic profiling and molecularly targeted treatment in this group of carcinomas.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.